Related Experiment Video
Updated: Aug 19, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
MDM2 is a central node in the p53 pathway: 12 years and counting
Gareth L Bond1, Wenwei Hu, Arnold J Levine
1School of Natural Sciences, Institute for Advanced Study, Princeton, NJ 08540, USA.
Abstract:
Twelve years ago, the Mdm2 oncogene was shown to bind to and inhibit the tumor suppressor protein, p53. During the past 12 years, both genetic and biochemical studies have demonstrated that Mdm2 is a key negative regulator of the tumor suppressor p53. Mdm2 and p53 form an oscillating auto-regulatory feedback loop, which is tightly controlled to allow the appropriate response to environmental stresses in order to suppress tumor formation. When Mdm2 activity is inappropriately heightened, as it is in many human tumors, p53 activity is attenuated and tumor susceptibility arises. The p53 gene is mutated in 50% of all human tumors, but in those tumors that retain wild type p53, inhibiting Mdm2 activity could activate p53 tumor suppression and therefore provide a therapeutic strategy for the treatment of cancer.
Insights
Mdm2 oncogene inhibits the tumor suppressor p53, a key regulator in preventing cancer. Inhibiting Mdm2 may restore p53 activity, offering a potential cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The Mdm2 oncogene negatively regulates the tumor suppressor protein p53.
- Mdm2 and p53 form a feedback loop critical for stress response and tumor suppression.
- Elevated Mdm2 activity attenuates p53, increasing susceptibility to cancer.
Purpose of the Study:
- To investigate the regulatory relationship between Mdm2 and p53.
- To explore the therapeutic potential of targeting Mdm2 in cancer treatment.
Main Methods:
- Genetic studies
- Biochemical studies
Main Results:
- Mdm2 is a key negative regulator of p53.
- Mdm2 and p53 form an oscillating auto-regulatory feedback loop.
- Inappropriate Mdm2 activity leads to p53 attenuation and tumor susceptibility.
Conclusions:
- Inhibiting Mdm2 activity can activate p53-mediated tumor suppression.
- Targeting Mdm2 presents a potential therapeutic strategy for cancers with wild-type p53.
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

